Nanyunja Carol, Sadoo Samantha, Mambule Ivan, Mathieson Sean R, Nyirenda Moffat, Webb Emily L, Mugalu J, Robertson Nicola J, Nabawanuka A, Gilbert Guillaume, Bwambale J, Martinello Kathryn, Bainbridge Alan, Lubowa Samson, Srinivasan Latha, Ssebombo H, Morgan Cathy, Hagmann Cornelia, Cowan Frances M, Le Doare Kirsty, Wintermark Pia, Kawooya Michael, Boylan Geraldine B, Nakimuli Annettee, Tann Cally J
MRC/UVRI & LSHTM Uganda Research Unit, Entebbe, Uganda.
London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Gates Open Res. 2022 Mar 3;6:10. doi: 10.12688/gatesopenres.13557.1. eCollection 2022.
Neonatal encephalopathy (NE) is a leading cause of child mortality worldwide and contributes substantially to stillbirths and long-term disability. Ninety-nine percent of deaths from NE occur in low-and-middle-income countries (LMICs). Whilst therapeutic hypothermia significantly improves outcomes in high-income countries, its safety and effectiveness in diverse LMIC contexts remains debated. Important differences in the aetiology, nature and timing of neonatal brain injury likely influence the effectiveness of postnatal interventions, including therapeutic hypothermia. This is a prospective pilot feasibility cohort study of neonates with NE conducted at Kawempe National Referral Hospital, Kampala, Uganda. Neurological investigations include continuous video electroencephalography (EEG) (days 1-4), serial cranial ultrasound imaging, and neonatal brain Magnetic Resonance Imaging and Spectroscopy (MRI/ MRS) (day 10-14). Neurodevelopmental follow-up will be continued to 18-24 months of age including Prechtl's Assessment of General Movements, Bayley Scales of Infant Development, and a formal scored neurological examination. The primary outcome will be death and moderate-severe neurodevelopmental impairment at 18-24 months. Findings will be used to inform explorative science and larger trials, aiming to develop urgently needed neuroprotective and neurorestorative interventions for NE applicable for use in diverse settings. The primary aims of the study are to assess the feasibility of establishing a facility-based cohort of children with NE in Uganda, to enhance our understanding of NE in a low-resource sub-Saharan African setting and provide infrastructure to conduct high-quality research on neuroprotective/ neurorestorative strategies to reduce death and disability from NE. Specific objectives are to establish a NE cohort, in order to 1) investigate the clinical course, aetiology, nature and timing of perinatal brain injury; 2) describe electrographic activity and quantify seizure burden and the relationship with adverse outcomes, and; 3) develop capacity for neonatal brain MRI/S and examine associations with early neurodevelopmental outcomes.
新生儿脑病(NE)是全球儿童死亡的主要原因,也是死产和长期残疾的重要原因。99%的新生儿脑病死亡发生在低收入和中等收入国家(LMICs)。虽然治疗性低温显著改善了高收入国家的治疗结果,但其在不同的低收入和中等收入国家环境中的安全性和有效性仍存在争议。新生儿脑损伤在病因、性质和时间上的重要差异可能会影响产后干预措施(包括治疗性低温)的有效性。这是一项在乌干达坎帕拉的卡韦姆佩国家转诊医院对患有新生儿脑病的新生儿进行的前瞻性试点可行性队列研究。神经学检查包括连续视频脑电图(EEG)(第1 - 4天)、系列头颅超声成像以及新生儿脑磁共振成像和波谱分析(MRI/MRS)(第10 - 14天)。神经发育随访将持续到18 - 24个月龄,包括普雷赫特尔的一般运动评估、贝利婴儿发育量表以及正式的神经学评分检查。主要结局将是18 - 24个月时的死亡和中度至重度神经发育障碍。研究结果将用于为探索性科学研究和更大规模的试验提供信息,旨在开发迫切需要的适用于不同环境的新生儿脑病神经保护和神经修复干预措施。该研究的主要目的是评估在乌干达建立一个基于机构的新生儿脑病患儿队列的可行性,加深我们对资源匮乏的撒哈拉以南非洲地区新生儿脑病的理解,并提供基础设施以开展关于神经保护/神经修复策略的高质量研究,以减少新生儿脑病导致的死亡和残疾。具体目标是建立一个新生儿脑病队列,以便:1)调查围产期脑损伤的临床过程、病因、性质和时间;2)描述脑电图活动,量化癫痫负担及其与不良结局的关系;3)发展新生儿脑MRI/S检查能力,并研究其与早期神经发育结局的关联。